New Antibody-drug Conjugate Shows Clinical Benefit for Advanced Platinum-resistant Ovarian Cancer
Summary:
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.
Improving cancer survival rates will require hard policy choices
Summary:
Integrated care and prevention strategies are key, but without careful planning — and sustainable funding — they risk falling short.
Special Report: The top 20 pharma companies by 2025 revenue
Summary:
A latest special report from FiercePharma on the global landscape of the pharmacutical industry in the challenging 2025, where only 4 out of 20 top drugmakers achieved growth
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer
Summary:
BioNTech and DualityBio reported clinically significant efficacy for trastuzumab pamirtecan in patients with HER2-expressing recurrent endometrial cancer, based on updated results from an ongoing Phase 1/2 trial.
Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
Summary:
Biogen has secured exclusive China rights to the late-stage immune antibody felzartamab through an $850 million deal with TJ Biopharma, consolidating global control of the anti-CD38 therapy as it advances toward potential approval for rare kidney diseases and multiple myeloma.
